Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Rosetta Resources, BioScrip Inc, PICO Holdings Inc: Funds Bullish On These Stocks Despite Poor Performance

Page 1 of 2

Ken Griffin’s Citadel Investment Group disclosed a large purchase in Rosetta Resources (NASDAQ:ROSE) this week. According to the 13G Form filed with the U.S. Securities and Exchange Commission, the hedge fund now owns 3.42 million common shares, representing 5.6% of the company’s outstanding stock. In another transaction that took place last week, Philip Hempleman’s Ardsley Partners augmented its exposure to BioScrip Inc (NASDAQ:BIOS) by 1.91 million shares. This latest move brought the firm’s holding to 3.53 million shares, which amount to 5.1% of the company’s outstanding stock. A 13D Form filed by Kelly Cardwell’s Central Square Management, revealed that fund has acquired more than 600,000 shares of PICO Holdings Inc (NASDAQ:PICO). Following this increase to its stake, the investment firm now holds 1.15 million shares of the company’s common stock.CITADEL INVESTMENT GROUP

Citadel Investment Group was founded by Ken Griffin in 1990 and today it is one of the world’s largest hedge funds. The firm has seen its assets under management grow considerably thanks to the use of a combination of advanced computer code, financial algorithms, and other technology-based methods. This has allowed the hedge fund to amass a diversified and balanced equity portfolio with a market value of $80 billion. Although even its largest holdings only account for at the most 1.5% of its portfolio, Citadel Investment Group has been aggressively purchasing shares of Newfield Exploration Co. (NYSE:NFX) as of late. The recently disclosed increase to its stake in Rosetta Resources is another large investment in an energy company.

Ardsley Partners is a Connecticut-based long/short equity fund that was founded in 1987 by Philip Hempleman. Although the firm invests on a global level, it has demonstrated a clear preference for equities belonging to chemical and chemical-related industries. Furthermore, Mr. Hempleman’s hedge fund focuses on value oriented growth stocks and currently boasts an equity portfolio value of around $758 million. According to its last 13F filing, Ardsley Partners’ top pick for the fourth quarter of 2014 was Gilead Sciences, Inc. (NASDAQ:GILD), which accounted for 9.5% of its equity portfolio.

Last week, the Connecticut-based hedge fund joined the large list of funds betting on BioScrip Inc (NASDAQ:BIOS), when it disclosed the large increase to its stake. Mario Gabelli’s GAMCO Investors is one of the major investment firms that recently acquired an important position in the company, purchasing around 5.86 million shares over the past few months. The mutual fund is currently the largest institutional investor betting on BioScrip amongst the funds we track, with a holding of 7.29 million shares. Hence, despite crumbling stock prices, which have seen shares drops 12.3% year-to-date, Ardsley Partners is not alone in its bullish stance towards the stock. And there is reason to remain optimistic, especially if the company’s trajectory up until August 2013 – when share prices reached a 10-year high – is taken into account. Furthermore, it seems BioScrip Inc (NASDAQ:BIOS) could be a great value oriented growth stock, which would fit well with the hedge fund’s investment philosophy.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!